Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teruhiko Fujii

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Current Medicinal Chemistry|March 14, 2008
Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1Teruhiko Fujii, Goro Yokoyama, Hiroki Takahashi, et al.
Cancer Research|May 19, 2005
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cellsAkira Hirata, Fumihito Hosoi, Miho Miyagawa, et al.
International Journal of Molecular Medicine|March 10, 2006
Regulation of vascular smooth muscle proliferation and migration by beta2-chimaerin, a non-protein kinase C phorbol ester receptorMitsuhide Maeda, Seiya Kato, Shintro Fukushima, et al.
Future Oncology (London, England)|March 17, 2009
YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cellsTeruhiko Fujii, Naoko Seki, Roka Namoto-Matsubayashi, et al.
Molecular Cancer Therapeutics|April 14, 2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferationMayumi Ono, Akira Hirata, Takuro Kometani, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 2005
[Combination immunotherapy using autologous tumor-stimulated lymphocytes and trastuzumab (Herceptin) for the patients with recurrent breast cancer]Uhi Toh, Teruhiko Fujii, Keisuke Miwa, et al.
Breast Cancer (Tokyo, Japan)|January 29, 2008
Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancerTeruhiko Fujii, Goro Yokoyama, Hiroki Takahashi, et al.
Surgery Today|April 27, 2004
Axillary lymph node recurrence of papillary thyroid microcarcinoma: report of a caseKenta Koike, Teruhiko Fujii, Hiroshi Yanaga, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 29, 2008
[Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer]Uhi Toh, Teruhiko Fujii, Mai Mishima, et al.
Surgery Today|February 2, 2008
Adenomyoepithelioma of the breast diagnosed by a mammotome biopsy: report of a caseToshiro Yahara, Rin Yamaguchi, Goro Yokoyama, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Current Medicinal Chemistry|March 14, 2008
Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1Teruhiko Fujii, Goro Yokoyama, Hiroki Takahashi, et al.
Cancer Research|May 19, 2005
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cellsAkira Hirata, Fumihito Hosoi, Miho Miyagawa, et al.
International Journal of Molecular Medicine|March 10, 2006
Regulation of vascular smooth muscle proliferation and migration by beta2-chimaerin, a non-protein kinase C phorbol ester receptorMitsuhide Maeda, Seiya Kato, Shintro Fukushima, et al.
Future Oncology (London, England)|March 17, 2009
YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cellsTeruhiko Fujii, Naoko Seki, Roka Namoto-Matsubayashi, et al.
Molecular Cancer Therapeutics|April 14, 2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferationMayumi Ono, Akira Hirata, Takuro Kometani, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 1, 2005
[Combination immunotherapy using autologous tumor-stimulated lymphocytes and trastuzumab (Herceptin) for the patients with recurrent breast cancer]Uhi Toh, Teruhiko Fujii, Keisuke Miwa, et al.
Breast Cancer (Tokyo, Japan)|January 29, 2008
Preclinical studies of molecular-targeting diagnostic and therapeutic strategies against breast cancerTeruhiko Fujii, Goro Yokoyama, Hiroki Takahashi, et al.
Surgery Today|April 27, 2004
Axillary lymph node recurrence of papillary thyroid microcarcinoma: report of a caseKenta Koike, Teruhiko Fujii, Hiroshi Yanaga, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 29, 2008
[Conventional chemotherapy combined with the repetitive immune cell transfer for patients with refractory advanced gastric cancer]Uhi Toh, Teruhiko Fujii, Mai Mishima, et al.
Surgery Today|February 2, 2008
Adenomyoepithelioma of the breast diagnosed by a mammotome biopsy: report of a caseToshiro Yahara, Rin Yamaguchi, Goro Yokoyama, et al.
Pageof 6